Company news

Myriad Genetics, Inc. news in 2025

Myriad Genetics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium

December 8, 2025

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

November 25, 2025

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

November 10, 2025

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs

November 9, 2025

Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference

November 5, 2025

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

November 2, 2025

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

October 30, 2025

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

October 26, 2025

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

October 13, 2025

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

October 8, 2025

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

September 22, 2025

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

September 3, 2025

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

September 2, 2025

ANGLE Announces Collaboration with Myriad Genetics

August 20, 2025

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

August 17, 2025

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

August 12, 2025

RxPreferred Benefits Expands Executive Leadership Team with Strategic Appointment and Key Promotions

August 12, 2025

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

August 5, 2025

Myriad Genetics Announces New $200 Million Credit Facility

July 30, 2025

Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025

July 28, 2025

Myriad Genetics Earns 2025 Great Place To Work Certification™

July 14, 2025

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

June 2, 2025

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

June 1, 2025

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

May 26, 2025

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

May 13, 2025

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

May 6, 2025

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

May 5, 2025

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

April 29, 2025

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

April 28, 2025

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

April 24, 2025

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

April 20, 2025

Myriad Genetics Announces Inducement Awards

April 7, 2025

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

April 6, 2025

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

February 26, 2025

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

February 23, 2025

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

February 23, 2025

Myriad Genetics Announces Senior Leadership Transition

February 23, 2025

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

February 18, 2025

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

February 17, 2025

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

February 5, 2025

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

February 4, 2025

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

February 4, 2025

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

January 28, 2025

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

January 22, 2025

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

January 20, 2025

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

January 14, 2025

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

January 8, 2025

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

January 6, 2025

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report

January 5, 2025

Calls in 2025

Decks in 2025